KemPharm, Inc.

Good afternoon and welcome to the ChemPharm second quarter 2022 corporate and financial results conference call. Currently, all callers have been placed in a listen-only mode, and following management's prepared remarks, the call will be opened up for questions. If you would like to ask a question at that time, please press star 1 on your telephone keypad. If you need to remove yourself from the queue, press star 2. At any time, if you should need operator assistance, press star 0. Please be advised that today's call is being recorded. I will now turn the call over to Nicole Oshner, ChemFarm's Vice President, Investor Relations and Corporate Communications. Thank you. Ma'am, you may begin.

Thank you. Good afternoon, and thank you for joining our call to discuss ChemFarm's second quarter 2022 financial and corporate results. Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including but not limited to statements about ChemPharm's expectations regarding future operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations Actual results may differ materially. ChemPharm disclaims any obligation to update or revise its forward-looking statements except as required by law. For more information regarding forward-looking statements, risks, and uncertainties can be found in ChemPharm's filings with the SEC, which are available on ChemPharm's website under the Investor Relations section. Speaking on today's call will be Travis Mickel, ChemPharm's President and CEO, and LeDwayne Clifton, CFO. In addition, we are very pleased to have Perry Sternberg, President and CEO of Corium Inc. on today's call to provide an update on the commercialization of Asteris. Following the remarks, Travis and LeDwayne will participate in a question and answer session. With that, it's my pleasure to introduce Travis.

Thank you, Nicole, and thank you everyone for joining us again today. We are pleased to have Perry with us on our second quarter results called today. We'll also be providing some product development updates from myself as well as the typical financial update from LaDwane, our CFO. So with that, I'm actually going to turn it over to Perry and just do a short intro here. Perry is a biotechnology and pharmaceutical industry leader with more than 25 years of commercial experience across a wide range of therapeutic areas and diverse markets. Prior to Corian, Perry served a dual role at Shire as the head of commercial for seven therapeutic area business units, as well as the chief commercial officer slash head of neuroscience division for the acquisition of Shire by Takeda in early 2019. I've had the pleasure to know Perry for a number of years, and, of course, we work closely together as partners on Staris. So with that, Perry, I appreciate your participation, and I'll let you take it from here.